MaaT Pharma S.A.
MAAT.PA · PAR
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | €2 | €1 | €2 | €1 |
| % Growth | 62.3% | -13.1% | 102.5% | – |
| Cost of Goods Sold | €1 | €2 | €1 | €1 |
| Gross Profit | €2 | -€0 | €1 | €0 |
| % Margin | 67.4% | -5.1% | 68.8% | 30.1% |
| R&D Expenses | €15 | €15 | €13 | €11 |
| G&A Expenses | €4 | €3 | €3 | €3 |
| SG&A Expenses | €4 | €3 | €3 | €3 |
| Sales & Mktg Exp. | €0 | €1 | €0 | €0 |
| Other Operating Expenses | -€2 | €0 | -€2 | -€2 |
| Operating Expenses | €16 | €17 | €14 | €12 |
| Operating Income | -€15 | -€18 | -€13 | -€11 |
| % Margin | -607.7% | -1,175.1% | -741.2% | -1,342.2% |
| Other Income/Exp. Net | -€0 | -€0 | -€2 | €0 |
| Pre-Tax Income | -€15 | -€18 | -€14 | -€11 |
| Tax Expense | €0 | -€2 | -€2 | €0 |
| Net Income | -€15 | -€16 | -€13 | -€11 |
| % Margin | -621.5% | -1,073.4% | -747% | -1,327.3% |
| EPS | -1 | -1.15 | -1.05 | -0.97 |
| % Growth | 13% | -9.5% | -8.2% | – |
| EPS Diluted | -1 | -1.15 | -1.05 | -0.97 |
| Weighted Avg Shares Out | 15 | 14 | 12 | 12 |
| Weighted Avg Shares Out Dil | 15 | 14 | 12 | 12 |
| Supplemental Information | – | – | – | – |
| Interest Income | €0 | €0 | €0 | €1 |
| Interest Expense | €0 | €1 | €0 | €1 |
| Depreciation & Amortization | €0 | €1 | €0 | €0 |
| EBITDA | -€15 | -€16 | -€13 | -€11 |
| % Margin | -603% | -1,101.7% | -734.4% | -1,329.9% |